Novo Nordisk Pharmatech showing cGMP quats at inaugural CPhI North America

Koege, Denmark: – Novo Nordisk Pharmatech A/S, the leading worldwide supplier of high-quality ingredients for the biopharmaceutical, pharmaceutical and personal care industries, will exhibit its high purity cGMP quaternary ammonium compounds (Quats) at the inaugural CPhI North America event in Philadelphia.

The Danish-based specialist will be exhibiting at stand at Booth 2358 at the Pennsylvania Convention Center, alongside its US distributor Brenntag.

FeF™ Quats range

The Novo Nordisk Pharmatech display will showcase the company’s expanded range of FeF™ branded Quats, manufactured in accordance with cGMP Guide ICH Q7 for Active Pharmaceutical Ingredients, the highest available standard using an innovative synthesis process.

“We will be able to show our American visitors that with more than 65 years experience, with have unrivalled knowledge of manufacturing many different types of Quats products,” said Marketing Manager Vanessa León.

Validation and traceability

“Because we understand the importance of using best quality ingredients in pharmaceutical products, we are able offer the highest quality on the market, including validated processes, complete traceability and complete documentation,” added Ms. León.

Novo Nordisk Pharmatech will show a range of products, including Benzalkonium Chloride, Cetrimide and Cetrimonium Bromide (CTAB) with high purity levels that make them ideally suited to pharmaceutical applications, acting as preservatives or active ingredients in many ophthalmic, nasal, oral and topical drugs and in a variety of solutions, ointments and creams. They can also be used as lysing or precipitating agents in vaccine production.

Multicompendial analysis

“Since our Quats are focused on life sciences and healthcare applications products, we analyze according to relevant multicompendial pharmacopoeias such as Ph.Eur., USP/NF, JP and BP,” explained Chantale Julien, Novo Nordisk Pharmatech Senior Product Manager for Quats.

“Using our compounds reduces the risk of deviations for biosimilar manufacturers who need to keep a strong focus on the manufacturing process of originator drugs,” said Julien, who will be part of the Novo Nordisk Pharmatech stand team, on hand to answer technical questions.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2015, Novo Nordisk reported world sales totaling 107,927 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About CPhI North America

CPhI North America is a new development of the highly successful CPhI worldwide franchise first established in 1989. Originally conceived as a chemical and pharmaceutical ingredients show, CPHI is now a global series of events for the whole pharmaceutical value chain, taking in events all over the world attracting more than 100,000 attendees annually.

The inaugural CPhI North America Expo is a three-day event opening May 16, 2017, at the Pennsylvania Convention Center in Philadelphia. It is branded as two shows in one, co-locating CPhI Connect with Informex, the fine and specialty chemicals expo.

CPhI Connect will comprise 80 hours of educational content and thought leadership for drug development, drug manufacturing and quality assurance professionals including three keynote sessions and 28 master classes focused on latest innovations in formulation development and drug manufacturing for small molecule pharmaceutical ingredients as well as hot topics including the future of biologics, outsourcing trends and regulatory horizon.

CPhI North America is staged by leading Global B2B events organizer and publisher UBM Live, with more information at: http://cphinorthamerica.com/conference